Top

Published in:

01-10-2008 | Original Article

Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy

Authors: Carmen Valbuena, Elísio Carvalho, Manuela Bustorff, Mariana Ganhão, Sandra Relvas, Rosete Nogueira, Fátima Carneiro, João Paulo Oliveira

Published in: Virchows Archiv | Issue 4/2008

Abstract

Fabry disease is an X-linked glycosphingolipidosis caused by deficiency of alpha-galactosidase. Progressive chronic kidney disease (CKD) is a major cause of morbidity and mortality in males. Although 40% of heterozygous females may develop renal involvement, pathologic data on Fabry nephropathy in heterozygotes are scarce. We reviewed the kidney biopsies of four affected females who had normal to slightly sub-normal renal function, two of them with overt proteinuria. Chronic non-specific degenerative lesions and glycosphingolipid accumulation per cell type were semi-quantitatively assessed by light and electron microscopy. Cellular distribution of glycosphingolipid deposits was best assessed on semithin sections. Podocyte effacement was seen only in proteinuric patients. Combined analysis of our data with those of two earlier series showed that glomerular sclerosis and tubulointerstitial fibrosis are predictors of proteinuria and CKD stage. There was no histopathological evidence supporting a major role of vascular damage in the early pathogenesis of Fabry nephropathy in females.

Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS et al (eds) The metabolic and molecular bases of inherited disease. 8th edn. McGraw Hill, New York, pp 3733–3774

Desnick RJ, Wasserstein MP, Banikazemi M (2001) Fabry disease (α-Galactosidase A deficiency): renal involvement and enzyme replacement therapy. In: Schieppati A, Daina E, Sessa A, Remuzzi G (eds) Rare kidney diseases (contributions to nephrology, vol 136). Karger, Basel, pp 174–192CrossRef

Desnick RJ, Brady R, Barranger J et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346PubMed

Ortiz A, Oliveira JP, Waldek S et al (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23:1600–1607PubMedCrossRef

Lyon MF (1962) Sex chromatin and gene action in the mammalian X chromosome. Am J Hum Genet 14:135–418PubMed

Deegan PB, Baehner AF, Barba Romero M-Á et al (2006) Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet 43:347–352PubMedCrossRef

Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab 93:112–128PubMedCrossRef

MacDermot KD, Holmes A, Miners AH (2001) Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females [Letter]. J Med Genet 38:769–775PubMedCrossRef

Thadhani R, Wolf M, West ML et al (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249–255PubMedCrossRef

10.

Gubler M-C, Lenoir G, Grünfeld J-P et al (1978) Early renal changes in hemizygous and heterozygous patients with Fabry’s disease. Kidney Int 13:223–235PubMedCrossRef

11.

Sessa A, Tosoni A, Nebuloni M et al (2002) Renal ultrastructural findings in Anderson–Fabry disease. J Nephrol 15:109–112PubMed

12.

Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13:S134–S138PubMed

13.

Fischer EG, Moore MJ, Lager DJ (2006) Fabry disease: a morphologic study of 11 cases. Mod Path 19:1295–1301CrossRef

14.

Sessa A, Meroni M, Battini G et al (2003) Renal involvement in Anderson–Fabry disease. J Nephrol 16:310–313PubMed

15.

Meehan SM, Junsanto T, Rydel JJ, Desnick RJ (2004) Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. Am J Kidney Dis 43:164–171PubMedCrossRef

16.

Warnock DG (2005) Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 14:87–95PubMedCrossRef

17.

Sessa A, Meroni M, Battini G et al (2003) Evolution of renal pathology in Fabry disease. Acta Paediatr Suppl 443:6–8

18.

Palmer BF (2007) Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 27:287–293PubMedCrossRef

19.

Pompen AWM, Ruiter M, Wyers HJG (1947) Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports. Acta Med Scand 128:234–255PubMed

20.

Colley JR, Miller DL, Hutt MSR et al (1958) The renal lesion in angiokeratoma corporis diffusum. Brit M J 1:1266–1268PubMedCrossRef

21.

Bethune JE, Landrigan PL, Chipman CD (1961) Angiokeratoma corporis diffusum universale (Fabry’s disease) in two brothers. New Engl J Med 264:1280–1285

22.

Henry EW, Rally CR (1963) The renal lesion in angiokeratoma corporis diffusum (Fabry’s disease). Can Med Assoc J 89:206–213PubMed

23.

Groot WP (1964) Angiokeratoma corporis diffusum Fabry (Thesaurismosis hereditaria Ruiter–Pompen–Wyers). Dermatologica 128:321–349

24.

Hartley MW, Miller RE, Dempsey HJ, Carroll JF (1964) Dysphospholipidosis in Fabry’s disease: a light and electron microscopic study. Ala J Med Sci 1:361–367PubMed

25.

Burda CD, Winder PR (1967) Angiokeratoma corporis diffusum universale (Fabry’s disease) in female subjects. Am J Med 42:293–301PubMedCrossRef

26.

Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122–138CrossRef

27.

Oliveira JP (2007) Staging of Fabry disease using renal biopsies. Clin Ther 29(Suppl A):S15–S16PubMedCrossRef

28.

Chobanian AV, Bakris GL, Black HR et al (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206–1252PubMedCrossRef

29.

Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef

30.

Rule AD, Larson TS, Bergstralh EJ et al (2004) Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 141:929–937PubMed

31.

Vervoort G, Willems HL, Wetzels JFM (2002) Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 17:1909–1913PubMedCrossRef

32.

Gehan EA, George SL (1970) Estimation of human body surface area from height and weight. Cancer Chemother Rep 54:225–235PubMed

33.

National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39(Suppl.1):S1–S266

34.

Desnick RJ, Allen KY, Desnick SJ et al (1973) Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 81:157–171PubMed

35.

Wiseman DA, Hawkins R, Numerow LM, Taub KJ (1990) Percutaneous renal biopsy utilizing real time, ultrasonic guidance and a semiautomated biopsy device. Kidney Int 38:347–349PubMedCrossRef

36.

Whittier WL, Korbet SM (2004) Renal biopsy: update. Curr Opin Nephrol Hypertens 13:661–665PubMedCrossRef

37.

Furness PN (2000) ACP best practice No 160: renal biopsy specimens. J Clin Pathol 53:433–438PubMedCrossRef

38.

Walker PD, Cavallo T, Bonsib SM, Ad Hoc Committee on Renal Biopsy Guidelines of the Renal Pathology Society (2004) Practice guidelines for the renal biopsy. Mod Path 17:1555–1563CrossRef

39.

Sternberg SS (ed) (1992) Histology for pathologists. Raven, New York

40.

Remuzzi G, Grinyò J, Ruggenenti P et al (1999) Early experience with dual kidney transplantation in adults using expanded donor criteria. J Am Soc Nephrol 10:2591–2598PubMed

41.

Meaney C, Blanch LC, Morris CP (1994) A nonsense mutation (R220X) in the α-galactosidase A gene detected in a female carrier of Fabry disease. Hum Mol Genet 3:1019–1020PubMedCrossRef

42.

Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med 345:9–16PubMedCrossRef

43.

Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749PubMedCrossRef

44.

Thurberg BL, Rennke H, Colvin RB et al (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933–1946PubMedCrossRef

45.

Svarstad E, Bostad L, Kaarbøe O et al (2005) Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry’s disease. Clin Nephrol 63:394–401PubMed

46.

Chade AR, Lerman A, Lerman OL (2005) Kidney in early atherosclerosis. Hypertension 45:1042–1049PubMedCrossRef

47.

Caetano ERSP, Zatz R, Saldanha LB, Praxedes JN (2001) Hypertensive nephrosclerosis as a relevant cause of chronic renal failure. Hypertension 38:171–176PubMed

48.

Olson JL, Schwartz MM (1998) The nephrotic syndrome: minimal change disease, focal segmental glomerulosclerosis, and miscellaneous causes. In: Jennette JC, Olson JL, Schwartz MM, Silva FG (eds) Heptinstall’s pathology of the kidney, 5th edn. Lippincott-Raven, Philadelphia, pp 187–257

49.

Pirani CL (1994) Evaluation of kidney biopsy specimens. In: Tisher CG, Brenner BM (eds) Renal pathology with clinical and functional correlations, 2nd edn. Lippincott, Philadelphia, pp 85–115

50.

Tosoni A, Nebuloni M, Zerbi P et al (2005) Ultrastructural study of renal involvement in two females with Anderson–Fabry disease. Ultrastruct Pathol 29:203–207PubMedCrossRef

51.

Faraggiana T, Churg J, Grishman E et al (1981) Light- and electron-microscopic histochemistry of Fabry’s disease. Am J Pathol 103:247–262PubMed

52.

Kriz W, Gretz N, Lemley KV (1998) Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 54:687–697PubMedCrossRef

53.

Kriz W, Lemley KV (1999) The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 8:489–497PubMedCrossRef

54.

Mundel P, Shankland SJ (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13:3005–3015PubMedCrossRef

55.

Ichikawa I, Ma J, Motojima M, Matsusaka T (2005) Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis. Curr Opin Nephrol Hypertens 14:205–210PubMedCrossRef

56.

Kawamura O, Sakuraba H, Itoh K et al (1997) Subclinical Fabry’s disease occurring in the context of IgA nephropathy. Clin Nephrol 47:71–75PubMed

57.

Yoshida A, Morozumi K, Takeda A et al (1994) Fabry-like laminated myelin body associated with IgA nephropathy. Nippon Jinzo Gakkai Shi 36:1303–1307PubMed

58.

Whybra C, Schwarting A, Kriegsmann J et al (2006) IgA nephropathy in two adolescent sisters heterozygous for Fabry disease. Pediatr Nephrol 21:1251–1256PubMedCrossRef

59.

Breunig F, Weidemann F, Strotmann J et al (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216–1221PubMedCrossRef

60.

Waldherr R, Rambausek M, Duncker WD, Ritz E (1989) Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 4:943–946PubMed

Title: Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy
Authors: Carmen Valbuena
Elísio Carvalho
Manuela Bustorff
Mariana Ganhão
Sandra Relvas
Rosete Nogueira
Fátima Carneiro
João Paulo Oliveira
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 4/2008
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-008-0653-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

Secondary sclerosing cholangitis after intensive care unit treatment: clues to the histopathological differential diagnosis

Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome

The pre-lymphatic pathway, the rooths of the lymphatic system in breast tissue: a 3D study

The microscopic (optical and SEM) examination of putrefaction fluid deposits (PFD). Potential interest in forensic anthropology

Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?

Toxic hepatic injury mimicking ascending cholangitis: is Pyrus amygdaliformis to blame?